EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access

Gut‑kidney axis in chronic kidney disease: Dysbiosis, uremic metabolites and therapeutic opportunities (Review)

Yinding Wang, Hanyu Zeng, Na Liu, Dong Yang

Molecular Medicine Reports · 2026

DOI: 10.3892/mmr.2026.14047 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Molecular Medicine Reports, 2026. Verfasst von Yinding Wang und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Nephrology, The Third Affiliated Hospital of Gansu University of Chinese Medicine, Baiyin, Gansu 730900, P.R. China. Hauptthemen laut MEDLINE: Dysbiosis, Renal Insufficiency, Chronic, Gastrointestinal Microbiome, Uremic Toxins. Die Arbeit nennt 135 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Chronic kidney disease (CKD) poses a notable global health burden. Beyond traditional pathways, the gut‑kidney axis has emerged as a potential contributor to disease progression. In the present narrative review, current evidence on the role of intestinal dysbiosis, characterized by reduced microbial diversity, depletion of beneficial short‑chain fatty acid producers and expansion of uremic toxin‑generating bacteria, in the accumulation of nephrotoxic metabolites (such as indoxyl sulfate, p‑cresyl sulfate and trimethylamine N‑oxide) is summarized. These toxins promote oxidative stress, inflammation and fibrosis, accelerating renal decline. By contrast, microbially derived short‑chain fatty acids exert protective effects. Although therapeutic strategies targeting the gut microbiome (including probiotics, prebiotics and adsorbents) and fecal microbiota transplantation (targeting the gut microbiome) exhibit potential in modulating toxin levels, evidence for clinical endpoint benefit remains insufficient. In the present review, mechanistic insights were critically evaluated, clinical intervention studies are systematically summarized in tabulated form and a roadmap for personalized, microbiota‑informed therapeutic strategies is proposed.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

DysbiosisRenal Insufficiency, ChronicGastrointestinal MicrobiomeUremic ToxinsKidneyHumansAnimalsPrebioticsProbioticsIndicanFecal Microbiota Transplantation

Stichwörter der Autor:innen

chronic kidney diseasedysbiosisgut‑kidney axisindoxyl sulfatemicrobiomeshort‑chain fatty acidstherapeutic strategiesuremic toxins

Substanzen

Uremic ToxinsPrebioticsIndican

Autor:innen und Institutionen

  • Department of Nephrology, The Third Affiliated Hospital of Gansu University of Chinese Medicine, Baiyin, Gansu 730900, P.R. China.
  • Department of Nephrology, Baiyin Hospital of Integrated Traditional Chinese and Western Medicine, Baiyin, Gansu 730900, P.R. China.

Zitieren

APA

Wang, Y., Zeng, H., Liu, N., & Yang, D. (2026). Gut‑kidney axis in chronic kidney disease: Dysbiosis, uremic metabolites and therapeutic opportunities (Review). Molecular Medicine Reports. https://doi.org/10.3892/mmr.2026.14047

Vancouver

Wang Y, Zeng H, Liu N, Yang D. Gut‑kidney axis in chronic kidney disease: Dysbiosis, uremic metabolites and therapeutic opportunities (Review). Molecular Medicine Reports. 2026. doi:10.3892/mmr.2026.14047

BibTeX
@article{Wang2026,
  author = {Wang, Yinding and Zeng, Hanyu and Liu, Na and Yang, Dong},
  title = {Gut‑kidney axis in chronic kidney disease: Dysbiosis, uremic metabolites and therapeutic opportunities (Review)},
  journal = {Molecular Medicine Reports},
  year = {2026},
  doi = {10.3892/mmr.2026.14047}
}
Kostenlos starten →